



## **HIGHLIGHTS**

# **2016 STATE PRESCRIPTION DRUG MONITORING PROGRAM (PMP) BILLS**

**Research current through November 8, 2016.**

This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.

© National Alliance for Model State Drug Laws (NAMSDL) and Sherry L. Green & Associates, LLC (SLGA). Research current as of November 8, 2016. Research is conducted using both nationwide legal database software and individual state legislative websites. This document may be reproduced in whole or in part for non-commercial purposes with full attribution to NAMSDL and SLGA. Please contact Sherry L. Green at [sgreen@namsdl.org](mailto:sgreen@namsdl.org) or at 505.692.0457 with additional updates or information that may be relevant to this document.

## **ADDITIONAL MONITORED SUBSTANCES**

### [IN SEA 161](#)

(Ephedrine and pseudoephedrine dispensed by prescription/drug order)

### [NE LB 471](#)

(All prescribed controlled substances as of 1/1/17, all prescribed substances as of 1/1/18)

### [WV SB 454](#)

(Opioid antagonists/naloxone)

## **FREQUENCY OF REPORTING (effective dates vary)**

### Daily/next business day/24 hours

#### [MD HB 437](#)

#### [NE LB 471](#)

#### [NH SB 576-FN-A](#)

#### [PA SB 1202](#)

(Act takes effect 60 days after passage)

[RI SB2823A](#) as amended (applies to dispensing of opioids)

#### [VT SB 243](#)

#### [VA SB 287](#)

#### [WI AB 364](#)

### Weekly

#### [AK SB 74](#)

(effective 7/17/17)

## **DATA RETENTION**

#### [GA HB 900](#)

(2 years)

[LA SB 56](#)

(Board of Pharmacy to issue rules for retention, archiving, and destruction of PMP information)

[MN SF 1440](#)

(As of 2020, data older than 24 months destroyed; data reported on or after 1/1/2020, destroy no later than 12 months)

## **DE-IDENTIFIED DATA**

[GA HB 900](#)

(Allows de-identified data for statistical, research, educational or grant application)

[HI SB 2915](#)

(Allows de-identified data for research/education to qualified personnel per agreement)

[IA SF 2102](#)

(Allows de-identified data for statistical, public research, public policy or educational purposes)

## **NON-PMP INFORMATION REPORTED TO PMP**

Deaths involving overdoses

[TN SB 1850](#)

[UT HB 149](#)

[WI AB 365](#)

Admissions to hospitals for overdoses

[UT HB 114](#)

Instances/experiences of opioid-related overdoses

[WI AB 365](#)

Convictions for specified violations of controlled substances/prescription drug laws

[UT HB 114](#)

Suspected violations of controlled substances/prescription drug laws

[WI AB 365](#)

Reports of stolen prescriptions

[WI AB 365](#)

Patient's voluntary non-opiate directive

[MA HB 4056](#)

## **ACCESS-DELEGATES**

New delegate authority – prescribers and pharmacists/dispensers

[AK SB 74](#)

[FL SB 964](#)

[GA HB 900](#)

[HI SB 2915](#)

[NH SB 576-FN-A](#)

New delegate authority - dispensers

[NE LB 471](#)

Modified existing delegate authority

[ID HB 374](#)

(Maximum of 4 delegates)

[CT HB 5053](#)

(Allows delegates who are not licensed health care professionals; special protocols for prescribing practitioners employed by or who provide services to a hospital)

[MD HB 437](#)

(Adds requirements that prescriber/pharmacist responsible for delegate and must take reasonable steps to ensure delegate competence)

[MN SF 1440](#)

(Delegates for health licensing board for certain complaints regarding licensees)

[VA HB 293](#)

(Allows delegates who are not licensed health care professionals)

## **ACCESS – NEW AUTHORIZED USERS**

### Medical examiner/coroner

[AK SB 74](#)

[HI SB 2915](#)

[ID HB 337](#)

[IN SEA 1278](#)

[NH SB 576-FN-A](#)

[UT SB 136](#)

### State Medicaid and Centers for Medicaid and Medicare Services (CMS)

[GA HB 900](#)

### State Medicaid

[AK SB 74](#)

### Medicaid managed care physician/pharmacist

[VA SB 491](#)

### Prescriber/dispenser consulting on treatment

[VA SB 287](#)

### Temporary medical fellowship permittee

[IN SEA 1278](#)

### Substance abuse counselor/individual authorized to treat substance abuse

[WI AB 364](#)

Impaired practitioner consultant

[FL SB 964](#)

Health care facilities and health care provider groups of five (5) or more providers

[WA HB 2730](#)

Board member monitoring licensee on probation

[UT SB 136](#)

Probation/parole officer

[UT HB 149](#)

Diversion committee member

[UT SB 136](#)

Legal, communications, and analytical employees of the Bureau of Narcotics and Dangerous Drugs

[OK HB 3201](#)

Third party designated by patient to receive notice that patient received controlled substances on a specific date

[UT HB 150](#)

## **MANDATED REGISTRATION**

New registration requirement for prescriber/practitioner and/or pharmacist

[AK SB 74](#)

(Dentists, physicians, advanced practice nurses, pharmacists)

[HI SB 2915](#)

(Practitioners, except veterinarians)

[ME LD 1646](#)

(Pharmacists; existing requirement for prescribers)

[MD HB 437](#)

(Prescribers, pharmacists)

[MN SF 1440](#)

(Prescribers, pharmacists)

[MS HB 462](#)

(Pharmacists; existing requirement for prescribers)

[NC HB 1030](#)

(Prescribers)

[PA SB 1202](#)

(ABC-MAP Board has duty to develop policies/procedures to require registration of all prescribers/dispensers)

Automated registration – part of controlled substances registration or upon application/renewal of license/authority

[HI SB 2915](#)

[ME LD 1646](#)

[RI SB 2823A](#) as amended

## **MANDATED USE**

New requirement to check PMP for prescribers and/or pharmacists/dispensers

[AK SB 74](#)

(Before prescribing or dispensing Schedule II-III controlled substance with exceptions)

[CA SB 482](#)

(Before first-time prescribing, ordering, administering, or furnishing of a Schedule II-IV controlled substance except for veterinarians, pharmacists, and other specified exemptions; check shall not be earlier than 24 hours or the previous business day prior to first-time prescribing, ordering, administering, or furnishing. Subsequent check every four (4) months if the substance remains part of the treatment)

[ME LD 1646](#)

(Initial prescribing of a benzodiazepine or an opioid. Subsequent check every 90 days as long as substance is renewed as part of treatment. Before dispensing a benzodiazepine or an opioid under specified circumstances. Exceptions may apply)

[MD HB 437](#)

(Before initiating course of treatment that includes prescribing or dispensing an opioid or benzodiazepine. Subsequent check every 90 days if treatment continues with the opioid or benzodiazepine. Pharmacists check if there is reasonable belief that patient is seeking drug for a nonmedical purpose. Exceptions may apply)

[NH SB 576-FN-A](#)

(Prescribing Schedule II-IV opioid for the treatment of pain. Subsequent check at least twice a year. Exceptions may apply)

[UT HB 375](#)

(Prescriber/dispenser of opioid for out-patient use deems a check necessary in his/her professional judgement to prevent opioid abuse)

[WI AB 364](#)

(Before practitioner issues a prescription order for the patient. Exceptions may apply)

Added/modified circumstances in which prescribers and/or pharmacists/dispensers are required to check the PMP

[AZ SB 1283](#)

(Before prescribing a Schedule II-IV opioid or benzodiazepine for a new course of treatment. Subsequent check at least quarterly while the substances remains part of the treatment. Exceptions may apply)

[CT HB 5053](#)

(Prescribing more than a 72 hour supply of a controlled substance. Check required at least every 90 days when prescribing other than a Schedule V nonnarcotic controlled substance for continuous or prolonged treatment. Prescribing a Schedule V nonnarcotic controlled substance for continuous or prolonged treatment requires a PMP check not less than annually. Exceptions may apply)

[IN SEA 297](#)

(Appropriate state agency shall develop best practices for opioid treatment by an opioid treatment provider that shall include a review of a patient's INSPECT report)

[MA HB 4056](#)

(Department of Health shall issue rules that requires a registered participant to check the PMP each time the participant issues a Schedule II-III narcotics prescription)

[NM SB 263](#)

(Prescribing/dispensing for the first time more than a four (4) day supply of an opioid. Check required at least every three (3) months during the continuing prescribing/dispensing of an opioid)



[PA SB 1202](#)

(A dispenser shall query the PMP before dispensing an opioid drug product or a benzodiazepine in specified circumstances. A prescriber shall query the PMP each time a patient is prescribed an opioid drug product or a benzodiazepine. Exception applies)

[RI SB2823A](#) as amended

(Before starting an opioid and before refilling or initiating opioid therapy with an intrathecal pump. Check required every three (3) months during continuous opioid therapy for pain for three (3) months or longer. Exceptions may apply)

[VT SB 243](#)

(Dispenser query of PMP in accordance with rules of the Commissioner of Health)

[VA HB 293](#)

(Initiating a new course of treatment that includes prescribing of opioids anticipated at outset to last more than 14 consecutive days. Exceptions may apply)

[WV SB 454](#)

(Before prescribing/dispensing medication assisted treatment, check required to ensure the patient is not seeking controlled substances from multiple sources and to assess potential adverse drug interactions. Exceptions may apply)

## **UNSOLICITED/PROACTIVE ALERTS/REPORTS**

[IN SEA 1278](#)

(Health care provider regulatory board to establish guidelines for exception reports)

[MD HB 437](#)

(Allows notice to prescriber/dispenser for possible violation of law or breach of occupational standards)

[AK SB 74](#)

(Allows notice to practitioners and pharmacists regarding patients)

[VA HB 657](#)

(Requires establishment of criteria for unusual patterns of prescribing/dispensing)

## **INTEGRATION OF PMP DATA**

[AZ SB 1283](#)

[IA SF 2102](#)

[OR HB 4124](#)

[RI HB 7847](#)

[UT HB 239](#)

**PLACEMENT OF PMP DATA IN PATIENT'S MEDICAL RECORD/FILE**

[IN SEA 1278](#)

[VA SB 287](#)